机构:[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[3]Neurological Imaging Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China重点科室诊疗科室研究所神经病学中心神经病学中心北京市神经外科研究所首都医科大学附属天坛医院[4]Department of Neuroradiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室医技科室放射科放射科首都医科大学附属天坛医院[5]Molecular Pathology Center, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China研究所北京市神经外科研究所首都医科大学附属天坛医院
The presence of contrast enhancement (CE) on magnetic resonance (MR) imaging is conventionally regarded as an indicator for tumor malignancy. However, the biological behaviors and molecular mechanism of enhanced tumor are not well illustrated. The aim of this study was to investigate the molecular profiles associated with anaplastic gliomas (AGs) presenting CE on postcontrast T1-weighted MR imaging. In this retrospective database study, RNA sequencing and MR imaging data of 91 AGs from the Cancer Genome Atlas (TCGA) and 64 from the Chinese Glioma Genome Atlas (CGGA) were collected. Gene set enrichment analysis (GSEA), significant analysis of microarray, generalized linear models, and Least absolute shrinkage and selection operator algorithm were used to explore radiogenomic and prognostic signatures of AG patients. GSEA indicated that angiogenesis and epithelial-mesenchymal transition were significantly associated with post-CE. Genes driving immune system response, cell proliferation, and focal adhesions were also significantly enriched. Gene ontology of 237 differential genes indicated consistent results. A 48-gene signature for CE was identified in TCGA and validated in CGGA dataset (area under the curve = 0.9787). Furthermore, seven genes derived from the CE-specific signature could stratify AG patients into two subgroups based on overall survival time according to corresponding risk score. Comprehensive analysis of post-CE and genomic characteristics leads to a better understanding of radiology-pathology correlations. Our gene signature helps interpret the occurrence of radiological traits and predict clinical outcomes. Additionally, we found nine prognostic quantitative radiomic features of CE and investigated the underlying biological processes of them.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81601452]; National Key Research and Development Plan [2016YFC0902500]; National High Technology Research and Development ProgramNational High Technology Research and Development Program of China [2015CB755500]; Beijing Postdoctoral Research FoundationChina Postdoctoral Science Foundation [2016ZZ-37, 2017-zz-121]; Beijing Natural Science FoundationBeijing Natural Science Foundation [7174295]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2017M620833]
第一作者机构:[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
共同第一作者:
通讯作者:
通讯机构:[1]Beijing Neurosurgical Institute, Capital Medical University, Beijing, China[2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[*1]Neurosurgical Institute, Capital Medical University, 6, Tiantanxili, Beijing 100050, China[*2]Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantanxili, Beijing 100050, China
推荐引用方式(GB/T 7714):
Liu Xing,Li Yiming,Sun Zhiyan,et al.Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas[J].CANCER MEDICINE.2018,7(9):4273-4283.doi:10.1002/cam4.1672.
APA:
Liu, Xing,Li, Yiming,Sun, Zhiyan,Li, Shaowu,Wang, Kai...&Jiang, Tao.(2018).Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas.CANCER MEDICINE,7,(9)
MLA:
Liu, Xing,et al."Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas".CANCER MEDICINE 7..9(2018):4273-4283